Stephane Thibault Selected Research

cobra cytotoxin I

12/2013

Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephane Thibault Research Topics

Disease

4	Neoplasms (Cancer) 01/2019 - 01/2013
3	Breast Neoplasms (Breast Cancer) 01/2019 - 04/2016
2	Neutropenia 01/2019 - 04/2016
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021
1	Leukemia 01/2021
1	Diarrhea 01/2019
1	Glucose Intolerance 11/2017
1	Cardiomegaly (Heart Hypertrophy) 11/2013
1	Triple Negative Breast Neoplasms 01/2013

Drug/Important Bio-Agent (IBA)

3	palbociclibIBA 01/2019 - 04/2016
1	AntigensIBA 01/2021
1	Anaplastic Lymphoma KinaseIBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	lorlatinibIBA 01/2021
1	Cyclin-Dependent Kinase 4IBA 01/2019
1	ribociclibIBA 01/2019
1	abemaciclibIBA 01/2019
1	XenobioticsIBA 01/2019
1	Estrogen Receptor Modulators (Antiestrogen)IBA 04/2016
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 04/2016
1	Cytotoxins (Cytolysins)IBA 12/2013
1	cobra cytotoxin IIBA 12/2013
1	bosutinibIBA 11/2013

Therapy/Procedure

2	Therapeutics 01/2021 - 01/2013
1	Oral Administration 01/2019
1	Drug Therapy (Chemotherapy) 01/2013